Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 2700+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 13 - 14, 2026

Apr 15, 2026

•

8 min read

Biotech & Pharma Updates | April 13 - 14, 2026

🧬 Novo Nordisk + OpenAI partner to integrate AI across drug discovery + manufacturing + corporate operations, Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery, Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline, Alamar Biosciences files for $159M IPO - protein sequencing and biomarker profiling tools, Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 12 - 13, 2026

Apr 14, 2026

•

8 min read

Biotech & Pharma Updates | April 12 - 13, 2026

🧬 Kailera plans $528.5M IPO to advance quartet of Chinese obesity assets, Eli Lilly's Jaypirca hits Ph3 endpoint for chronic lymphocytic leukemia in fixed-duration combination therapy, AbbVie + Haisco Pharmaceutical partner on pain compounds development - up to $715M deal value

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 9 - 12, 2026

Apr 13, 2026

•

7 min read

Biotech & Pharma Updates | April 9 - 12, 2026

🧬 Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids, Vivatides Therapeutics raises $54M Series A for RNA delivery beyond the liver, GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers

Anis Fahandej-Sadi

Long Form Content

Biopunk & Community Labs: The Future For Biotech?

Apr 11, 2026

•

24 min read

Biopunk & Community Labs: The Future For Biotech?

Why the biotech of the future might be a lot smaller and a lot more nimble

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 8 - 9, 2026

Apr 10, 2026

•

8 min read

Biotech & Pharma Updates | April 8 - 9, 2026

🧬 Eli Lilly launches obesity pill Foundayo at $149 - intensifying GLP-1 competition with Novo Nordisk's Wegovy, Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months, Avalyn Pharma plans IPO - developing inhalable IPF treatments for lung disease, Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention, Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155 + $50M investment

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 7 - 8, 2026

Apr 9, 2026

•

8 min read

Biotech & Pharma Updates | April 7 - 8, 2026

🧬 Jeito Capital raises $1.2B fund - investing in European clinical-stage drugmakers, Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing - $482M potential value, Gilead Sciences pauses M&A after acquiring Arcellx + Ouro Medicines + and Tubulis within six weeks

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 6 - 7, 2026

Apr 8, 2026

•

7 min read

Biotech & Pharma Updates | April 6 - 7, 2026

🧬 Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal, E2 raises $80M Series C for next-gen thrombectomy treatment commercialization, Vertex Pharmaceuticals + Halozyme partner on Hypercon drug delivery technology - $15M upfront plus milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 5 - 6, 2026

Apr 7, 2026

•

7 min read

Biotech & Pharma Updates | April 5 - 6, 2026

🧬 Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition - gaining rare obesity disorder drug Vykat XR, Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs, Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 1 - 5, 2026

Apr 6, 2026

•

9 min read

Biotech & Pharma Updates | April 1 - 5, 2026

🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 13 - 14, 2026

Biotech & Pharma Updates | April 12 - 13, 2026

Biotech & Pharma Updates | April 9 - 12, 2026

Biopunk & Community Labs: The Future For Biotech?

Biotech & Pharma Updates | April 8 - 9, 2026

Biotech & Pharma Updates | April 7 - 8, 2026

Biotech & Pharma Updates | April 6 - 7, 2026

Biotech & Pharma Updates | April 5 - 6, 2026

Biotech & Pharma Updates | April 1 - 5, 2026

TLDR Biotech

FAQ

Media Partners